Diagnostic and prognostic performance of serum GPC3 and PIVKA-II in AFP-negative hepatocellular carcinoma and establishment of nomogram prediction models

Table 4 Comparative analysis of annual survival rates of HCC-N patients based on risk stratification of GPC3 and PIVKA-II

Groups	Number	Median survival (month)	1-year OS, n(%)	2-year OS, n(%)	3-year OS, n(%)
GPC3-lowrisk (≤ 0.124 ng/mL)	54	42.473	47 (87.04%)	41 (75.93%)	34 (62.96%)
GPC3-highrisk (> 0.124 ng/mL)	50	28.165	35 (70.00%)	22 (44.00%)	19 (38.00%)
P value		0.002	0.034	0.001	0.011
PIVKA-II-lowrisk (≤ 274 mAU/mL)	53	40.007	44 (83.02%)	35 (66.04%)	32 (60.38%)
PIVKA-II-highrisk (> 274 mAU/mL)	51	30.125	38 (74.51%)	28 (54.90%)	21 (41.18%)
P value		0.028	0.288	0.245	0.050

GPC3, detectable serum GPC3; PIVKA-II, detectable serum PIVKA-II; OS, overall survival
GPC3-lowrisk vs. GPC3-highrisk, were compared by the chi-square test or Fisher’s exact test and P < 0.05 was statistically significant
PIVKA-II-lowrisk vs. PIVKA-II-highrisk, were compared by the chi-square test or Fisher’s exact test and P < 0.05 was statistically significant

ISSN: 1471-2407